Objective To explore the clinical effects of modified Huangqi Chifeng Decoction（MHCD

黄芪赤风汤） in treatment of patients with IgA nephropathy of Qi deficiency

blood stasis and pathogenic wind and heat toxin syndrome（QDBSPWHT） as well as its possible mechanism. Methods Sixty patients with IgA nephropathy of QDBSPWHT syndrome were randomized into treatment group and control group with 30 patients in each group. Both groups were given telmisartan tablets 80 mg each time

once daily

and the treatment group was additionally administered with modified MHCD 1 bag each time

twice daily

while the control group was added with placebo of modified MHCD 1 bag each time

twice daily; the treatments of both groups lasted for 16 weeks. The scores of traditional Chinese medicine（TCM） syndromes

24-hour urine protein quantification（24 hU-TP）

serum creatinine（Scr）

serum alanine aminotransferase（ALT）

serum aspartate aminotransferase（AST）

and expressions of urinary podocyte-associated podocalyxin and nephropathy protein were observed. The clinical effects and symptom-related clinical effects were assessed. Results The total effective rate of the treatment group was 93.10%

significantly higher than 65.52% of the control group（P<0.05）; regarding the symptom-related effects

the total effective rate of the treatment group was 89.66%

which was significantly higher than 13.79% of control group（P<0.01）. The levels of 24 hU-TP at the 4 th

8 th

12 nd

and 16 th week in both groups significantly decreased compared to those before treatment（P<0.05 or P<0.01）

and more decrease was found in treatment group（P<0.01）. The TCM symptoms scores of treatment group at the 4 th

8 th

12 nd

and 16 th week and that of control group at the 16 th week significantly decreased compared to those before treatment（P<0.05 or P<0.01）

and the comparisons between groups at the 8 th

12 nd

and 16 th week found larger scores decreases in the treatment group（P<0.01）. The Scr level of treatment group significantly decreased at the 8 th and 16 th week（P<0.01）

and more decrease was seen in treatment group than control group at the 16 th week（P<0.05）. Both the expression of podocalyxin and that of nephin significantly decreased（P<0.01） after treatment

and the treatment group had lower expressions than control group（P<0.05）. Conclusion Modified MHCD can increase the clinical effects and improve symptoms of patients with IgA nephropathy of QDBSPWHT syndrome

and the mechanism may be related to the protection of urinary podocytes.